Technical Analysis for ACOR - Acorda Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 2.7 3.05% 0.08
ACOR closed up 3.05 percent on Friday, August 16, 2019, on 1.96 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Down Down
See historical ACOR trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Hammer Candlestick Bullish 3.05%
New 52 Week Low Weakness 3.05%
Wide Bands Range Expansion 3.05%
Oversold Stochastic Weakness 3.05%
New 52 Week Closing Low Bearish 12.97%
New 52 Week Low Weakness 12.97%
Wide Bands Range Expansion 12.97%

Older signals for ACOR ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Chemistry Health Biopharmaceutical Antibodies Autoimmune Diseases Clinical Trial Multiple Sclerosis Central Nervous System Disorders Heart Failure Spinal Cord Injury Treatment Of Heart Failure
Is ACOR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 29.75
52 Week Low 2.27
Average Volume 1,299,351
200-Day Moving Average 12.5583
50-Day Moving Average 6.2024
20-Day Moving Average 4.5905
10-Day Moving Average 2.811
Average True Range 0.4443
ADX 59.2
+DI 10.326
-DI 48.5469
Chandelier Exit (Long, 3 ATRs ) 5.7971
Chandelier Exit (Short, 3 ATRs ) 3.6029
Upper Bollinger Band 8.4941
Lower Bollinger Band 0.6869
Percent B (%b) 0.26
BandWidth 170.072977
MACD Line -1.2387
MACD Signal Line -1.1203
MACD Histogram -0.1184
Fundamentals Value
Market Cap 125.7 Million
Num Shares 46.6 Million
EPS -0.94
Price-to-Earnings (P/E) Ratio -2.87
Price-to-Sales 2.27
Price-to-Book 1.76
PEG Ratio 0.51
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.15
Resistance 3 (R3) 3.17 3.03 3.08
Resistance 2 (R2) 3.03 2.92 3.03 3.05
Resistance 1 (R1) 2.87 2.85 2.95 2.85 3.02
Pivot Point 2.73 2.73 2.78 2.73 2.73
Support 1 (S1) 2.57 2.62 2.65 2.55 2.38
Support 2 (S2) 2.43 2.55 2.43 2.35
Support 3 (S3) 2.27 2.43 2.33
Support 4 (S4) 2.25